

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A
(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2022

INMED PHARMACEUTICALS INC.
(Exact Name of Company as Specified in Charter)

British Columbia (State or Other Jurisdiction of Incorporation)	001-39685 (Commission File Number)	98-1428279 (IRS Employer Identification No.)
InMed Pharmaceuticals Inc. Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada (Address of Principal Executive Offices)		V6C 1B4 (Zip Code)

Company's telephone number, including area code: (604) 669-7207

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	INM	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Explanatory Note

On June 22, 2022, InMed Pharmaceuticals Inc. (the “Company”) filed a Form 8-K (the “Original Form 8-K”). This Amendment to Form 8-K is being filed to correct a typographical error in the Original Form 8-K. In connection with such clarification, the corrected content under Item 3.01 is stated herein. Except as set forth herein, the remainder of the Original Form 8-K remains unchanged.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

The below sentence amends and restates the original first sentence under Item 3.01 in its entirety.

“On June 17, 2022, the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market (“Nasdaq”), notifying it that based upon the closing bid price of the Company’s common shares for the last 30 consecutive business days, the Company no longer meets the minimum bid price of \$1 per share, as required under Nasdaq Listing Rule 5550(a)(2).”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMED PHARMACEUTICALS INC.

Date: June 23, 2022

By: /s/ Brenda Edwards

Brenda Edwards

Interim Chief Financial Officer